JAM3 as a Prognostic Biomarker in Muscle-Invasive Urothelial Carcinoma: Correlation With Therapeutic Response, and Survival Outcomes

Launched by ZEINAB YAHIA ZAKI · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the role of a protein called JAM3 in patients with muscle-invasive urothelial carcinoma, a type of bladder cancer that is more aggressive and often harder to treat. The researchers want to see if measuring the levels of JAM3 in biopsy samples can help predict how well patients will respond to chemotherapy and how long they might survive after treatment. By understanding JAM3 better, the study aims to improve how doctors choose treatments for patients and potentially lead to more personalized care.

To participate in this trial, individuals must be at least 18 years old and have a confirmed diagnosis of muscle-invasive bladder cancer that is eligible for chemotherapy. Unfortunately, patients with cancer that has already spread to other parts of the body cannot join. If you qualify, you can expect to provide a biopsy sample, and your treatment response and health outcomes will be closely monitored. This study is not yet recruiting participants, but it represents an important step toward finding more effective ways to treat bladder cancer in the future.

Gender

ALL

Eligibility criteria

• • Inclusion criteria
• • 1. Patients above 18 years
• • 2. Histopathological confirmed TCC
• • 3. Patients with MIBC
• • 4. Patients eligible for neoadjuvant chemotherapy
• • Exclusion criteria
• • 1. Patients with metastatic disease
• • 2. Patients ineligible for systemic therapy